Glucose, Obesity, Metabolic Syndrome, and Diabetes. Relevance to Incidence of Heart Failure

Journal of the American College of Cardiology

Volumn 55, Issue 4, 2010, Pages 283-293

  Horwich, Tamara B ^a   Fonarow, Gregg C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

diabetes; glucose; heart failure; metabolic syndrome; obesity

Indexed keywords

ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CLOPIDOGREL; ENALAPRIL; GLUCOSE; IRBESARTAN; LOSARTAN; PERINDOPRIL; PLACEBO; RAMIPRIL; SIMVASTATIN;

CLINICAL TRIAL; DIABETES MELLITUS; HEART FAILURE; HUMAN; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; OBESITY; PRIORITY JOURNAL; REVIEW;

DIABETES COMPLICATIONS; GLUCOSE; HEART FAILURE; HUMANS; LIFE STYLE; METABOLIC SYNDROME X; OBESITY; RISK FACTORS;

EID: 74049143053     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2009.07.029     Document Type: Review

References (73)

1. Lloyd-Jones D., Adams R., Carnethon M., et al. Heart disease and stroke statistics-2009 update. A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 119 (2009) e21-e181
2. Braunwald E. Cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. N Engl J Med 337 (1997) 1360-1369
3. Fang J., Mensah G.A., Croft J.B., and Keenan N.L. Heart failure-related hospitalization in the U.S., 1979 to 2004. J Am Coll Cardiol 52 (2008) 428-434
4. Schocken D.D., Benjamin E.J., Fonarow G.C., et al. Prevention of heart failure: a scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Clinical Cardiology, Cardiovascular Nursing, and High Blood Pressure Research; Quality of Care and Outcomes Research Interdisciplinary Working Group; and Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation 117 (2008) 2544-2565
5. Levy D., Larson M.G., Vasan R.S., Kannel W.B., and Ho K.K. The progression from hypertension to congestive heart failure. JAMA 275 (1996) 1557-1562
6. He J., Ogden L.G., Bazzano L.A., Vupputuri S., Loria C., and Whelton P.K. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic follow-up study. Arch Intern Med 161 (2001) 996-1002
7. Kannel W.B., Hjortland M., and Castelli W.P. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 34 (1974) 29-34
8. Bertoni A.G., Hundley W.G., Massing M.W., Bonds D.E., Burke G.L., and Goff Jr. D.C. Heart failure prevalence, incidence, and mortality in the elderly with diabetes. Diabetes Care 27 (2004) 699-703
9. Nichols G.A., Gullion C.M., Koro C.E., Ephross S.A., and Brown J.B. The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 27 (2004) 1879-1884
10. Bibbins-Domingo K., Lin F., Vittinghoff E., et al. Predictors of heart failure among women with coronary disease. Circulation 110 (2004) 1424-1430
11. Iribarren C., Karter A.J., Go A.S., et al. Glycemic control and heart failure among adult patients with diabetes. Circulation 103 (2001) 2668-2673
12. Stratton I.M., Adler A.I., Neil H.A.W., et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 321 (2000) 405-412
13. Pazin-Filho A., Kottgen A., Bertoni A., et al. HbA1c as a risk factor for heart failure in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) study. Diabetologia 51 (2008) 2197-2204
14. Held C., Gerstein H.C., Yusuf S., et al. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation 115 (2007) 1371-1375
15. Nichols G.A., Arondekar B., and Herman W.H. Complications of dysglycemia and medical costs associated with nondiabetic hyperglycemia. Am J Manag Care 14 (2008) 791-798
16. Ingelsson E., Sundstrom J., Arnlov J., Zethelius B., and Lind L. Insulin resistance and risk of congestive heart failure. JAMA 294 (2005) 334-341
17. Arnlov J., Lind L., Zethelius B., et al. Several factors associated with the insulin resistance syndrome are predictors of left ventricular systolic dysfunction in a male population after 20 years of follow-up. Am Heart J 142 (2001) 720-724
18. Ärnlöv J., Lind L., Sundström J., Andrén B., Vessby B., and Lithell H. Insulin resistance, dietary fat intake and blood pressure predict left ventricular diastolic function 20 years later. Nutr Metab Cardiovasc Dis 15 (2005) 242
19. van Heerebeek L., Hamdani N., Handoko M.L., et al. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 117 (2008) 43-51
20. Neubauer S. The failing heart-an engine out of fuel. N Engl J Med 356 (2007) 1140-1151
21. Taegtmeyer H., McNulty P., and Young M.E. Adaptation and maladaptation of the heart in diabetes: Part I: general concepts. Circulation 105 (2002) 1727-1733
22. Witteles R.M., and Fowler M.B. Insulin-resistant cardiomyopathy: clinical evidence, mechanisms, and treatment options. J Am Coll Cardiol 51 (2008) 93-102
23. Szczepaniak L.S., Victor R.G., Orci L., and Unger R.H. Forgotten but not gone: the rediscovery of fatty heart, the most common unrecognized disease in America. Circ Res 101 (2007) 759-767
24. Van De Borne P., Hausberg M., Hoffman R.P., Mark A.L., and Anderson E.A. Hyperinsulinemia produces cardiac vagal withdrawal and nonuniform sympathetic activation in normal subjects. Am J Physiol 276 (1999) R178-R183
25. Hoffman R.P., Hausberg M., Sinkey C.A., and Anderson E.A. Hyperglycemia without hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Diabetes Complications 13 (1999) 17-22
26. Biondi-Zoccai G.G.L., Abbate A., Liuzzo G., and Biasucci L.M. Atherothrombosis, inflammation, and diabetes. J Am Coll Cardiol 41 (2003) 1071-1077
27. Alexander J.K. Obesity and the heart. Heart Dis Stroke 2 (1993) 317-321
28. Kenchaiah S., Evans J.C., Levy D., et al. Obesity and the risk of heart failure. N Engl J Med 347 (2002) 305-313
29. Kenchaiah S., Sesso H.D., and Gaziano J.M. Body mass index and vigorous physical activity and the risk of heart failure among men. Circulation 119 (2009) 44-52
30. Loehr L.R., Rosamond W.D., Poole C., et al. Association of multiple anthropometrics of overweight and obesity with incident heart failure: the Atherosclerosis Risk in Communities study. Circ Heart Fail 2 (2009) 18-24
31. Morricone L., Malavazos A.E., Coman C., Donati C., Hassan T., and Caviezel F. Echocardiographic abnormalities in normotensive obese patients: relationship with visceral fat. Obes Res 10 (2002) 489-498
32. Bahrami H., Bluemke D.A., Kronmal R., et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 51 (2008) 1775-1783
33. Vasan R.S., Sullivan L.M., Roubenoff R., et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart study. Circulation 107 (2003) 1486-1491
34. Frankel D.S., Vasan R.S., D'Agostino Sr. R.B., et al. Resistin, adiponectin, and risk of heart failure: the Framingham Offspring study. J Am Coll Cardiol 53 (2009) 754-762
35. Lieb W., Sullivan L.M., Harris T.B., et al. Plasma leptin levels and incidence of heart failure, cardiovascular disease and total mortality, in the elderly. Diabetes Care 32 (2009) 612-616
36. Butler J., Rodondi N., Zhu Y., et al. Metabolic syndrome and the risk of cardiovascular disease in older adults. J Am Coll Cardiol 47 (2006) 1595-1602
37. Ingelsson E., Arnlov J., Lind L., and Sundstrom J. Metabolic syndrome and risk for heart failure in middle-aged men. Heart 92 (2006) 1409-1413
38. Li C., Ford E.S., McGuire L.C., and Mokdad A.H. Association of metabolic syndrome and insulin resistance with congestive heart failure: findings from the Third National Health and Nutrition Examination Survey. J Epidemiol Community Health 61 (2007) 67-73
39. Folsom A.R., Yamagishi K., Hozawa A., Chambless L.E., and Atherosclerosis Risk in Communities Study. Absolute and attributable risks of heart failure incidence in relation to optimal risk factors. Circ Heart Fail 2 (2009) 11-17
40. Skyler J.S., Bergenstal R., Bonow R.O., et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA Diabetes Trials: a position statement of the American Diabetes Association and a Scientific Statement of the American College of Cardiology Foundation and the American Heart Association. J Am Coll Cardiol 53 (2009) 298-304
41. Duckworth W., Abraira C., Moritz T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360 (2009) 129-139
42. Patel A., MacMahon S., Chalmers J., et al., ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358 (2008) 2560-2572
43. Gerstein H.C., Miller M.E., Byington R.P., et al., Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358 (2008) 2545-2559
44. Ray KK, Seshasai SRK, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet; 373:1765-72.
45. Montori V.M., and Fernandez-Balsells M. Glycemic control in type 2 diabetes: time for an evidence-based about-face?. Ann Intern Med 150 (2009) 803-808
46. Del Prato S. Megatrials in type 2 diabetes. From excitement to frustration?. Diabetologia 52 (2009) 1219-1226
47. McAlister F.A., Eurich D.T., Majumdar S.R., and Johnson J.A. The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy. Eur J Heart Fail 10 (2008) 703-708
48. Nichols G.A., Koro C.E., Gullion C.M., Ephross S.A., and Brown J.B. The incidence of congestive heart failure associated with antidiabetic therapies. Diabetes Metab Res Rev 21 (2005) 51-57
49. Holman R.R., Paul S.K., Bethel M.A., Matthews D.R., and Neil H.A.W. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359 (2008) 1577-1589
50. Delea T.E., Edelsberg J.S., Hagiwara M., Oster G., and Phillips L.S. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care 26 (2003) 2983-2989
51. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279-89.
52. Erdmann E., Charbonnel B., Wilcox R.G., et al. Pioglitazone use and heart failure in patients with type 2 diabetes and preexisting cardiovascular disease: data from the PROactive Study (PROactive 08). Diabetes Care 30 (2007) 2773-2778
53. Dargie H.J., Hildebrandt P.R., Riegger G.A.J., et al. A randomized, placebo-controlled trial assessing the effects of rosiglitazone on echocardiographic function and cardiac status in type 2 diabetic patients with New York Heart Association functional class I or II heart failure. J Am Coll Cardiol 49 (2007) 1696-1704
54. Knowler W.C., Barrett-Connor E., Fowler S.E., et al., Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
55. Bosch J., Yusuf S., Gerstein H.C., et al., DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. N Engl J Med 355 (2006) 1551-1562
56. DREAM Trial Investigators, Gerstein H.C., Yusuf S., Bosch J., et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368 (2006) 1096-1105
57. Dagenais G.R., Gerstein H.C., Holman R., et al., DREAM Trial Investigators. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care 31 (2008) 1007-1014
58. Shai I., Schwarzfuchs D., Henkin Y., et al. Weight loss with a low-carbohydrate, mediterranean, or low-fat diet. N Engl J Med 359 (2008) 229-241
59. Sacks F.M., Bray G.A., Carey V.J., et al. Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates. N Engl J Med 360 (2009) 859-873
60. Hunt S.A., Abraham W.T., Chin M.H., et al., American College of Cardiology Foundation/American Heart Association. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 53 (2009) e1-e90
61. Arnold J.M.O., Yusuf S., Young J., et al. Prevention of heart failure in patients in the Heart Outcomes Prevention Evaluation (HOPE) study. Circulation 107 (2003) 1284-1290
62. Brenner B.M., Cooper M.E., de Zeeuw D., et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
63. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317 (1998) 703-713
64. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317 (1998) 713-720
65. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355 (2000) 253-259
66. Kjekshus J., Pedersen T.R., Olsson A.G., Faergeman O., and Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 3 (1997) 249-254
67. Horwich T.B., Fonarow G.C., Hamilton M.A., MacLellan W.R., Woo M.A., and Tillisch J.H. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol 38 (2001) 789-795
68. Kalantar-Zadeh K., Block G., Horwich T., and Fonarow G.C. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol 43 (2004) 1439-1444
69. Eshaghian S., Horwich T.B., and Fonarow G.C. An unexpected inverse relationship between HbA1c levels and mortality in patients with diabetes and advanced systolic heart failure. Am Heart J 151 (2006) 91.e1-91.e6
70. Horwich T.B., and Fonarow G.C. Reverse epidemiology beyond dialysis patients: chronic heart failure, geriatrics, rheumatoid arthritis, COPD, and AIDS. Semin Dial 20 (2007) 549-553
71. Remme W., Boccanelli A., Cline C., et al. Increasing awareness and perception of heart failure in Europe and improving care-rationale and design of the SHAPE Study. Cardiovasc Drugs Ther 18 (2004) 153-159
72. Remme W.J., McMurray J.J., Hobbs F.D., et al. Awareness and perception of heart failure among European cardiologists, internists, geriatricians, and primary care physicians. Eur Heart J 29 (2008) 1739-1752
73. Remme W.J., McMurray J.J., Rauch B., et al. Public awareness of heart failure in Europe: first results from SHAPE. Eur Heart J 26 (2005) 2413-2421